ORIC-533 is an orally active, highly selective, AMP-competitive CD73 inhibitor that potently blocks adenosine production with sub-nanomolar affinity (Ka 0.03 nM). In multiple myeloma, ORIC-533 restores and enhances the cytotoxicity of the immune system against tumor cells through multiple immunological mechanisms, including reversing the immunosuppressive microenvironment, inducing immunogenic cell death, and activating dendritic cells, T cells and NK cells, with no direct toxicity to normal cells. The combination of ORIC-533 with daratumumab (HY-P9915) synergistically enhances anti-tumor efficacy, significantly increases intratumoral CD8+ T cell infiltration and inhibits tumor growth in vivo[1][2].
Molekulargewicht:
605.93
CAS Nummer:
[2641306-62-7]
Formel:
C20H29ClN9O9P
Target-Kategorie:
CD73
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
